About Salarius Pharmaceuticals, Inc.
https://www.salariuspharma.comSalarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing.
CEO
Frederick E. Pierce
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 29, 2015
Method of going public IPO
Full time employees 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $4.91 M
52w High $0.90
52w Low $0.51
P/E -0.03
Volume 271.32K
Outstanding Shares 6.38M
About Salarius Pharmaceuticals, Inc.
https://www.salariuspharma.comSalarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing.
CEO
Frederick E. Pierce
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 29, 2015
Method of going public IPO
Full time employees 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0